Presentation is loading. Please wait.

Presentation is loading. Please wait.

Overall survival in the IFCT trial comparing a single agent therapy arm (vinorelbine or gemcitabine) and the doublet carboplatin plus weekly paclitaxel.

Published byJohnathan Cole Modified over 5 years ago

Similar presentations

Presentation on theme: "Overall survival in the IFCT trial comparing a single agent therapy arm (vinorelbine or gemcitabine) and the doublet carboplatin plus weekly paclitaxel."— Presentation transcript:

1 Overall survival in the IFCT trial comparing a single agent therapy arm (vinorelbine or gemcitabine) and the doublet carboplatin plus weekly paclitaxel arm in patients aged ≥70 years with advanced non-small cell lung cancer. Overall survival in the IFCT trial comparing a single agent therapy arm (vinorelbine or gemcitabine) and the doublet carboplatin plus weekly paclitaxel arm in patients aged ≥70 years with advanced non-small cell lung cancer. Elisabeth Quoix breathe 2012;9:26-34 ©2012 by European Respiratory Society

Download ppt "Overall survival in the IFCT trial comparing a single agent therapy arm (vinorelbine or gemcitabine) and the doublet carboplatin plus weekly paclitaxel."

Similar presentations

Advances and Emerging Therapy for Lung Cancer

Advances and Emerging Therapy for Lung Cancer
Www.OncologyEducation.com ESMO 2011 Lung Cancer AVAPERL Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.

ESMO 2011 Lung Cancer AVAPERL Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.
Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content.

Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content.
Weekly Paclitaxel Combined with Monthly Carboplatin versus Single-Agent Therapy in Patients Age 70 to 89: IFCT-0501 Randomized Phase III Study in Advanced.

Weekly Paclitaxel Combined with Monthly Carboplatin versus Single-Agent Therapy in Patients Age 70 to 89: IFCT-0501 Randomized Phase III Study in Advanced.
Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)
Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Comparative Toxicity Profiles of Two Platinum Doublets: Real Life Experience from a Cancer Unit Jessop S, Jeffs Y P, Thomas E, Azher M, Adu Poku K, Sa'D.

Comparative Toxicity Profiles of Two Platinum Doublets: Real Life Experience from a Cancer Unit Jessop S, Jeffs Y P, Thomas E, Azher M, Adu Poku K, Sa'D.
Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis 

Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis 
Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer -

Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer -
Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial  Susanne M.

Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial  Susanne M.
The Nurse View: Management of Pancreatic Cancer

The Nurse View: Management of Pancreatic Cancer
Table 1 Baseline patient characteristics

Table 1 Baseline patient characteristics
Patient Case 1 Patient Case 1: PET/CT Scan.

Patient Case 1 Patient Case 1: PET/CT Scan.
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer  Robert Klein, MS, Catherine.

Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer  Robert Klein, MS, Catherine.
Volume 52, Issue 1, Pages (July 2007)

Volume 52, Issue 1, Pages (July 2007)
Thomas A. d‘Amato, MD, PhD, Rodney J

Thomas A. d‘Amato, MD, PhD, Rodney J
Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.

Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.
Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.
Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

Similar presentations

Ads by Google